In 1966, researchers at the Albert Einstein College of Medicine pulled a peptide out of the thymus gland and figured it was just another immune regulator. They were wrong — or at least, they were selling it short. Thymosin beta-4 turned out to be expressed in nearly every cell in the body, and its role in tissue repair, cell migration, and wound healing has made it one of the most studied peptides in regenerative research.
TB-500 is the synthetic version researchers actually work with. Here’s what three decades of published data show.
This compound is supplied exclusively for in vitro and preclinical research. It is not intended for human consumption, therapeutic application, or diagnostic use.
First, the Biology: What Thymosin Beta-4 Actually Does
Thymosin beta-4 (Tβ4) is a 43-amino-acid peptide found in almost every nucleated cell type, with especially high concentrations in platelets, wound fluid, and developing tissues. Its primary intracellular job: regulating how cells build their structural scaffolding.
Specifically, Tβ4 sequesters G-actin (the monomeric building blocks of the cytoskeleton), controlling when and how these monomers polymerize into the filamentous actin networks that give cells their shape, movement, and ability to migrate. That might sound abstract, but it’s the molecular basis of wound healing — cells need to move to close a wound, and Tβ4 is one of the key regulators of that movement.
The Active Fragment: Ac-SDKP
When Tβ4 gets broken down in the body, one of its fragments — Ac-SDKP (the first four amino acids, acetylated) — has its own biological activity. This fragment has been studied for anti-fibrotic and anti-inflammatory properties independent of the parent peptide. It’s naturally present in human plasma and regulated by angiotensin-converting enzyme (ACE), which is why some researchers have drawn connections between ACE inhibitor therapy and Tβ4 biology.
What the Research Shows
Wound Healing and Cell Migration
This is where the bulk of the evidence lives. Malinda et al. (1999) published the first systematic demonstration that Tβ4 promotes wound healing, showing accelerated closure in both in vitro scratch assays and a full-thickness dermal wound model in rats. The mechanism: Tβ4 promoted endothelial cell migration, angiogenesis (new blood vessel formation), and keratinocyte migration — the three processes you need for wound repair.
Philp et al. (2004) expanded this to corneal wound healing, demonstrating faster epithelial wound closure and reduced inflammation in a rat corneal injury model. This became one of the more clinically advanced applications — RegeneRx Biopharmaceuticals developed RGN-259, a Tβ4-based eye drop that entered human clinical trials for dry eye and neurotrophic keratopathy.
Cardiac Repair
The cardiac research is what really put Tβ4 on the map in regenerative medicine. Bock-Marquette et al. (2004) published a landmark paper in Nature showing that Tβ4 improved survival and cardiac function in a mouse model of myocardial infarction when administered after coronary artery ligation. The proposed mechanisms included:
- Activation of Akt (protein kinase B) survival signaling → reduced cardiomyocyte death
- Promotion of angiogenesis in ischemic tissue → improved blood supply to damaged heart
- Recruitment of cardiac progenitor cells → potential for actual tissue regeneration
Smart et al. (2011) followed up in Nature with evidence that Tβ4 could “prime” epicardial progenitor cells to differentiate into new cardiomyocytes — suggesting regenerative potential beyond simply protecting existing cells from death.
Neurological Protection
Tβ4 research extends into the nervous system. Morris et al. (2010) studied Tβ4 in a traumatic brain injury (TBI) model and found improved functional outcomes, reduced inflammation, increased angiogenesis, and enhanced neurogenesis in the hippocampus. Xiong et al. (2012) reported similar findings in a stroke model, with Tβ4 treatment improving neurological function scores and increasing oligodendrocyte progenitor cells — the cells responsible for myelination (insulating nerve fibers).
Anti-Inflammatory and Anti-Fibrotic Effects
Beyond acute wound healing, Tβ4 has been studied for reducing the chronic inflammation and fibrosis (scar tissue formation) that follows tissue injury. Research in liver, lung, and kidney fibrosis models has shown that both Tβ4 and its Ac-SDKP fragment can reduce collagen deposition and inflammatory cytokine expression — shifting the healing response toward functional tissue repair rather than scar formation.
TB-500 vs Thymosin Beta-4: What Researchers Should Know
TB-500 is a synthetic peptide corresponding to the active region of thymosin beta-4 — specifically the region containing the actin-binding domain (amino acids 17-23: LKKTETQ). It’s not identical to full-length Tβ4 but includes the key functional sequence responsible for the cell migration, angiogenesis, and wound-healing properties observed in Tβ4 research.
Researchers use TB-500 rather than full-length Tβ4 for practical reasons: it’s easier and cheaper to synthesize, more stable, and contains the biologically active sequence. Most of the published literature uses full-length Tβ4, but the overlapping active region means TB-500 research findings are generally interpreted in the context of the broader Tβ4 literature.
The BPC-157 + TB-500 Question
Researchers frequently study TB-500 alongside BPC-157, since both peptides have been investigated for tissue repair — but through different mechanisms. BPC-157 appears to work primarily through angiogenesis, nitric oxide pathways, and growth factor modulation, while TB-500 acts through actin regulation and cell migration. The different mechanisms have led to interest in whether combined administration produces complementary effects. For a detailed comparison, see our BPC-157 vs TB-500 article.
Product Specifications
- Active Sequence: Contains LKKTETQ actin-binding domain
- Molecular Weight: ~4,963 g/mol
- CAS Number: 77591-33-4 (Thymosin Beta-4)
- Physical Form: Sterile lyophilized white powder
- Purity: ≥99% (verified by HPLC)
- Solubility: Freely soluble in bacteriostatic water
Key References
- Malinda KM, et al. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368.
- Philp D, et al. Thymosin β4 promotes corneal wound healing. Invest Ophthalmol Vis Sci. 2004;45(4):1034-1040.
- Bock-Marquette I, et al. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432:466-472.
- Smart N, et al. De novo cardiomyocytes from within the activated adult heart after injury. Nature. 2011;474:640-644.
- Morris DC, et al. Thymosin β4 improves functional neurological outcome in a rat model of TBI. Neuroscience. 2010;169:674-682.
All compounds at Chameleon Peptides are independently tested at Janoshik Analytical. Browse TB-500 5mg or explore the BPC-157 + TB-500 combo. For related tissue repair research, see BPC-157 and GHK-Cu.